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Abstract We previously reported that adrenomedullin (AM), a
vasodilating hormone secreted from blood vessels, promotes pro-
liferation and migration of human umbilical vein endothelial
cells (HUVECs). In this study, we examined the ability of
AM to promote vascular regeneration. AM increased the phos-
phorylation of Akt in HUVECs and the e¡ect was inhibited by
the AM antagonists and the inhibitors for protein kinase A
(PKA) or phosphatidylinositol 3-kinase (PI3K). AM promoted
re-endothelialization in vitro of wounded monolayer of HU-
VECs and neo-vascularization in vivo in murine gel plugs. These
e¡ects were also inhibited by the AM antagonists and the in-
hibitors for PKA or PI3K. The ¢ndings suggest that AM plays
signi¢cant roles in vascular regeneration, associated with PKA-
and PI3K-dependent activation of Akt in endothelial cells, and
possesses therapeutic potential for vascular injury and tissue
ischemia.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Vascular regeneration is an essential event in recovery from
endothelial injury or tissue ischemia. Thus, therapeutic strat-
egies to promote re-endothelialization or neo-vascularization
are now highlighted as promising treatment for atherosclerotic
or ischemic diseases [1,2]. Many vasoactive substances se-
creted from endothelial cells (vascular hormones) have been
reported to regulate not only vascular tone but also remodel-
ing or regeneration. We revealed that C-type natriuretic pep-
tide (CNP) is secreted from endothelial cells [3] and gene
transfer of CNP promoted endothelial regeneration [4,5] and
ischemia-induced angiogenesis [6] in vivo. We also reported
that NPs directly promote endothelial regeneration in vitro
[7]. In this way, NPs/cGMP/cGMP-dependent kinase (cGK)
cascade is elucidated to be involved in the regulation of vas-
cular regeneration.
Adrenomedullin (AM) is a potent vasorelaxant peptide that
was originally isolated from human pheochromocytoma cells
on the basis of its e¡ect to elevate cAMP levels in rat platelets
[8,9]. Recently, mice genetically engineered to overexpress or
underexpress the AM gene were developed to determine the in
vivo signi¢cance of AM [10^12]. Mice overexpressing the AM
gene in their vasculature showed reduced blood pressure. On
the other hand, mice lacking the AM gene did not survive the
embryonic stage and showed abnormal vascular structure and
subcutaneous hemorrhage. These observations suggest the sig-
ni¢cance of AM in vascular morphogenesis and regulation of
vascular tone in vivo. AM has been shown to be present in
atherosclerotic lesions and its secretion has been demonstrated
to be augmented by in£ammatory cytokines such as interleu-
kin-1, TNF-K, and lipopolysaccharide [13]. Furthermore, hyp-
oxia-responsive elements were identi¢ed in the AM gene and
hypoxic conditions were reported to induce its expression and
secretion from HUVECs [14]. These ¢ndings suggest the sig-
ni¢cance of AM for atherogenesis and angiogenesis.
Based on these ¢ndings, together with our recent report to
show that AM enhanced proliferation and migration of cul-
tured endothelial cells [15], we hypothesized that AM/cAMP/
protein kinase A (PKA) cascade might have the potency to
promote vascular regeneration. In this study, we tried to clar-
ify whether AM has bene¢cial e¡ects on vascular regeneration
in the physiological in vitro model for endothelial regenera-
tion and in vivo neo-vascularization in murine gel plugs.
2. Materials and methods
2.1. Materials and cell culture
All agents used were commercially available. Human AM, rat AM,
proadrenomedullin N-terminal 20 peptide (PAMP), and the two AM
antagonists, AM(22^52) and calcitonin gene-related peptide (8^37)
(CGRP(8^37)) were purchased from the Peptide Institute (Osaka, Ja-
pan). The two PKA inhibitors, adenosine 3P,5P-cyclic monophosphor-
othioate Rp-isomer (Rp-cAMP) and myristoylated PKA inhibitor
peptide sequence (14^22) cell-permeable (PKA Inh. Peptide), the
two phosphatidylinositol 3-kinase (PI3K) inhibitors, LY294002 and
wortmannin, and a cAMP analog, 8-Br-cAMP, were purchased from
Calbiochem (San Diego, CA, USA). Vascular endothelial growth fac-
tor (VEGF) was purchased from Peprotech (London, UK).
HUVECs (Clonetics, Waltersville, MD, USA) were grown in the
basic medium containing 2% fetal bovine serum (FBS) and growth
supplements (EGM-2; Clonetics). Cell cultures between passages 4
and 6 were used for each experiment.
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2.2. Western blot analysis of phosphorylated Akt
HUVECs were treated with or without AM (1038 mol/l) and they
were harvested 30 min after the treatments otherwise indicated. West-
ern blotting was performed according to a standard protocol, as we
described previously [16]. Akt activity was evaluated by the ratio of
phosphorylated Akt to total Akt detected by phospho-Akt (Ser473)
and Akt antibody (Cell Signaling, Beverly, MA, USA), respectively.
To evaluate Akt activation in endothelial injury, arti¢cial wounds
were made by a blue-tip at intervals of 5 mm on an over-con£uent
monolayer of HUVECs. Densitometric assays were done and the re-
sults were presented as fold increase compared to the control.
2.3. Wound healing assay in vitro
To examine whether AM promotes endothelial regeneration in vi-
tro, wound healing assay was carried out as we described previously
[7]. In the report, we con¢rmed that this assay could evaluate overall
activity of endothelial proliferation and migration. Brie£y, HUVECs
were grown to over-con£uent in six-well plates and a wound of ap-
proximately 2 mm width was made by a cell scraper. Cells were
allowed to repair the wound for 40 h in the medium containing
0.5% FBS with or without experimental agents. The wounded mono-
layer was photographed before and after the incubation period and
the re-endothelialized area was evaluated.
2.4. Gel plug assay in vivo
To examine the ability of AM to induce neo-vascularization in vivo,
we used murine MATRIGEL plug assay, as described previously [17].
Mice were handled with care according to accepted ethical guidelines.
Nude mice were anesthetized with pentobarbiturate (80 mg/kg) and
400 Wl per plug of growth factor-reduced phenol red-free MATRI-
GEL (Becton Dickinson, Bedford, MA, USA) was injected into the
abdomen of 6^8 week old male KSN-nude mice (Japan SLC; Hama-
matsu, Japan) subcutaneously. A mouse was injected two gels sym-
metrically in the abdomen, gels with and without experimental agents.
On day 0, 4, 7, 14, and 21, the margins of the subcutaneous plugs
were marked and the mean blood £ow and the size of the plugs were
estimated by a laser Doppler perfusion image analyzer (Moor instru-
ments, Devon, UK). Blood £ow in the plug was calculated by the
formula: (blood £ow)= (mean blood £ow)U(plug size). The ratio of
the blood £ow of the two plugs in the same mouse, an agent-contain-
ing plug to its control plug, was considered to be the index of the
angiogenic activity of the agent.
The gel plugs were resected from mice on day 21 and stained with
rat anti-mouse PECAM-1 (Pharmingen, San Diego, CA, USA) and
the number of PECAM-1 positive cells in the plug was estimated as
capillary density. 1-mm thick slices were also processed and stained
with rat anti-mouse PECAM-1 and a £uorescent agent, Alexa Flour
488 conjugated goat anti-rat IgG (Molecular Probes, Eugene, OR,
USA) for the observation with a confocal microscope (LSM5 PAS-
CAL; Carl Zeiss, Oberkochen, Germany) that can reconstruct the 3D
structure of the plug from the obtained consecutive images. In this
way, small capillaries in the plug were visualized stereoscopically.
2.5. Statistics
All data are expressed as the meanQS.E.M. Statistical analysis was
performed with ANOVA (analysis of variance) or Student’s t-test.
Values of P6 0.05 were considered to be statistically signi¢cant.
3. Results
3.1. AM activated Akt in HUVECs in a PKA- and
PI3K-dependent manner
Fig. 1A demonstrates a time course of the phosphorylation
of Akt at amino acid residue 473 (serine) after the treatment
with AM (1038 mol/l) on HUVECs. Akt phosphorylation was
augmented within 15 min and peaked at 30 min.
To examine Akt activation in endothelial damage, we made
arti¢cial wounds in a con£uent monolayer of HUVECs as
described in Section 2. The endothelial injury itself increased
Akt phosphorylation and the addition of AM to the injured
endothelium further augmented the increase (Fig. 1B).
AM-induced phosphorylation of Akt was inhibited by the
two AM antagonists, AM(22^52) (1035 mol/l) and CGRP-
(8^37) (1035 mol/l). The PKA inhibitors, Rp-cAMP (1035
mol/l) and PKA Inh. Peptide (5U1037 mol/l), and the inhib-
itors for PI3K, LY294002 (1035 mol/l) and wortmannin (1037
mol/l), also suppressed Akt phosphorylation signi¢cantly
(Fig. 1C).
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Fig. 1. E¡ect of AM on Akt activation in HUVECs. A: Time course of Akt phosphorylation in AM-treated HUVECs. Cells were treated with
AM (1038 mol/l) and harvested at the indicated times. B: E¡ect of arti¢cial wounds and AM on Akt phosphorylation. Wounds were made at
intervals of 5 mm on an over-con£uent monolayer of HUVECs treated with or without AM. Cells were harvested 30 min after the treatments
and phosphorylated Akt was detected. C: E¡ect of the AM antagonists and the inhibitors for PKA or PI3K on AM-induced Akt phosphoryla-
tion in HUVECs. Cells were pre-incubated with these inhibitors for 15 min before the administration of AM. They were harvested 30 min after
the treatment and phosphorylated Akt was detected. Densitometric analyses were done and the ratio of phosphorylated Akt to total Akt is pre-
sented as fold increases compared to the control. #: P6 0.05; *: P6 0.01 versus the control (panels A and B) or the AM-treated group with-
out inhibitors (panel C); 2 :P6 0.01 versus the control (panel C), n=3.
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3.2. AM promoted re-endothelialization of the wounded
monolayer of HUVECs through a PKA- and
PI3K-dependent pathway
Fig. 2 shows the closure of wounded endothelium incubated
with FBS 0.5% (control) (Fig. 2A), accompanied with AM
(1038 mol/l) (Fig. 2B), or VEGF (50 ng/ml) (Fig. 2C) for
40 h. Accelerated wound closure was observed in the group
treated with AM, as well as that treated with VEGF. Fig. 2D
shows the dose-dependent e¡ect of AM on endothelial regen-
eration in comparison with VEGF and PAMP. AM promoted
the wound closure signi¢cantly and dose-dependently. The
increase of re-endothelialized area by 1038 mol/l AM was
33.6%Q7.1% over the control (P6 0.01, n=12). On the other
hand, PAMP, a hypotensive peptide that is synthesized from
the same precursor of AM, had no signi¢cant e¡ect on endo-
thelial regeneration.
We next examined the e¡ect of the same inhibitors at the
same concentrations which were used in Akt phosphorylation
assay and had a signi¢cant inhibitory e¡ect on AM-induced
Akt activation. The two AM antagonists and the inhibitors
for PKA or PI3K at those concentrations suppressed AM
(1038 mol/l)-induced endothelial regeneration without a¡ect-
ing basal wound closure (Table 1).
In addition, 8-Br-cAMP (1039 mol/l) mimicked the AM
action to promote endothelial regeneration in wound healing
assay (21.8%Q5.0% over the control, P6 0.01, n=8).
Fig. 2. E¡ect of AM on endothelial regeneration in wound healing assay in vitro. Wounded monolayer of HUVECs was incubated for 40 h.
A^C: Representative photographs of re-endothelialized monolayer incubated for 40 h with the medium containing 0.5% FBS (control) (panel
A), accompanied by AM (panel B), or VEGF (panel C). D: Dose-dependent e¡ect of AM on endothelial regeneration in comparison to VEGF
and PAMP. *: P6 0.01 versus the control, n=12.
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3.3. AM augmented blood £ow in the plug through a PKA- and
PI3K-dependent pathway
Fig. 3A demonstrates a representative image of the blood
£ow analysis of gel plugs on day 21. The AM-containing plug
presented signi¢cantly higher blood perfusion compared to its
control plug. The blood £ow of the 1035 mol/l AM-containing
plug on day 21 was 29.4%Q8.1% higher than that on day 0
(P6 0.01, n=12; Fig. 3B).
The e¡ects of the inhibitors on the AM-induced increase in
blood £ow were examined. Inclusion of the AM antagonists
and the inhibitors for PKA or PI3K in AM-containing plugs
signi¢cantly suppressed AM (1037 mol/l)-induced augmenta-
tion of blood £ow (Table 2).
The inhibitors at the doses used in the MATRIGEL plug
assay had no signi¢cant e¡ect on basal blood £ow (Table 2)
and the number of neo-vessels (data not shown) of gel plugs
without AM. They did not have any signi¢cant toxic e¡ects.
3.4. AM increased capillary density in gel plugs
Microscopic observation of whole and sliced plugs revealed
Fig. 3. E¡ect of AM on blood perfusion in murine gel plug assay. A: Blood £ow measurement by a laser Doppler perfusion image analyzer. A
representative view of a mouse injected with an AM-containing gel (1035 mol/l) and a control gel is shown. The high-£ow area is depicted in
red to white and the low-£ow in green to black. B: Time course of the e¡ect of AM on blood £ow in gel plugs. Blood £ow on each day was
measured by the laser Doppler perfusion image analyzer and compared to that on day 0. #: P6 0.05; *: P6 0.01 versus the blood £ow on
day 0. n=12 (AM 1035 mol/l group), 8 (AM 1037 mol/l and vehicle groups), and 4 (AM 1039 mol/l group).
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enhanced neo-vascularization in AM-containing plugs (Fig.
4E,F) compared to their control plugs (Fig. 4A,B). The capil-
lary density estimated from PECAM-1 immuno-reactivity
(Fig. 4D,H) was signi¢cantly and dose-dependently increased
in AM-containing plugs (18.2 Q 2.8 per mm2 in the control,
35.7 Q 5.7 per mm2 in the 1035 mol/l AM-containing plug on
day 21; P6 0.01 versus the control, n=9; Fig. 4I). We also
con¢rmed increased capillary network in the AM-containing
plug by observation with a confocal microscope that could
visualize the 3D structure of capillaries of approximately 10
Wm diameter (Fig. 4C,G).
4. Discussion
In this study, we showed that AM provokes endothelial Akt
activation in a PKA- and PI3K-dependent manner and dem-
onstrated that AM promotes endothelial regeneration in vitro
and increases blood £ow and capillary density in gel plugs in
vivo through a PKA- and PI3K-dependent pathway.
AM-induced Akt activation in rat aortic tissues has been
shown in a previous report [18]. In this study, we further
con¢rmed that AM-induced Akt activation occurs in cultured
endothelial cells. We also demonstrated that Akt is activated
by the arti¢cial wounds on HUVECs. Furthermore, we re-
vealed that AM increases wound-induced Akt activation.
Akt has been shown to regulate survival, migration, and nitric
oxide production in endothelium [19]. In addition, constitutive
Akt signaling in endothelium has been reported to be su⁄-
cient to promote angiogenesis in a rabbit hindlimb ischemia
model [20]. Therefore, Akt activation in endothelium can be
regarded as a key event in transduction of the angiogenic
signal [21]. In the present study, AM-induced vascular regen-
Fig. 4. E¡ect of AM on neo-vascularization in the gel plug. Gel plugs were harvested with underlying skin from mice on day 21 and angiogenic
signs were microscopically examined. A^H: Representative images of a whole and sliced AM (1037 mol/l)-containing plug (panels E and F) are
shown, in comparison to the control plug (panels A and B). The plugs were stained with PECAM-1 to visualize neo-vessels. Immunochemically
stained and £uorescent-labeled sections of an AM-containing plug (panels G and H) are shown, as compared to the control (panels C and D).
The £uorescent-labeled sections were observed with a confocal microscope that can re-construct the 3D structure of small capillaries. I: Dose-
dependent e¡ect of AM on capillary density in the plugs determined by PECAM-1 immuno-reactivity on day 21. #: P6 0.05; *: P6 0.01 ver-
sus the control. n=9. Green: £uorescent-labeled PECAM-1 (panels C and G); brown: immunochemically stained PECAM-1 (panels D and
H); arrows: neo-vessels in AM-containing plugs (panels F and H).
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eration both in vitro and in vivo was suppressed by PI3K
inhibitors. Therefore, it is suggested that AM regulates neo-
vascularization via enhancement of endothelial Akt activity
following PI3K activation.
There are also several reports that imply the involvement of
the cAMP/PKA cascade in vascular regeneration. However,
whether PKA activation promotes or inhibits vascular regen-
eration is controversial [22,23]. In the present study, AM-in-
duced vascular regeneration both in vitro and in vivo was
signi¢cantly abrogated by the two PKA inhibitors, and 8-
Br-cAMP simulated the e¡ect of AM. Therefore, the cAMP/
PKA cascade is supposed to have potency to promote vascu-
lar regeneration, at least in our experimental conditions. We
also revealed that AM-induced Akt activation is suppressed
by the inhibitors for not only PI3K but also for PKA. These
results suggest the signi¢cance of the cAMP/PKA cascade on
the regulation of Akt activity, which can induce vascular re-
generation. The molecular mechanism in PKA-induced Akt
activation is now under investigation.
In MATRIGEL plug assay, it has been reported that 10^
100 times higher concentrations of substances than those used
in cell culture experiments were required to exert enough in-
£uence in gel plugs [24,25]. Based on these previous reports,
we planned to use higher concentrations of AM in MATRI-
GEL plug assay in vivo than in wound healing assay in vitro.
As a result, the e¡ective concentrations of AM were revealed
to be 1039^1037 mol/l in vitro and 1037^1035 mol/l in vivo.
The optimal concentrations of AM in vitro for cultured endo-
thelial cells were similar to previous reports [26]. The di¡er-
ence between the e¡ective concentrations in vitro and in vivo
observed in our present study was also compatible with pre-
vious reports [24,25].
In conclusion, we demonstrated that AM provokes endo-
thelial Akt activation and promotes vascular regeneration
both in vitro and in vivo through a PKA- and PI3K-depen-
dent pathway. These ¢ndings suggest the usefulness of AM as
a new therapeutic agent for vascular injury, atherosclerotic
diseases and tissue ischemia.
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